MAINZ BIOMED NV (MYNZ) Stock Price, Forecast & Analysis
USA - NASDAQ:MYNZ - NL0015000LC2 - Common Stock
MYNZ Key Statistics, Chart & Performance
The current stock price of MYNZ is 1.26 USD. In the past month the price decreased by -19.23%. In the past year, price decreased by -84.82%.
MYNZ Latest News, Press Relases and Analysis
MYNZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.76 | 413.38B | ||
| AMGN | AMGEN INC | 15.62 | 183.96B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25 | 111.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.65 | 74.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 903.02 | 60.37B | ||
| INSM | INSMED INC | N/A | 41.72B | ||
| NTRA | NATERA INC | N/A | 28.28B | ||
| BIIB | BIOGEN INC | 9.84 | 24.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.88 | 21.34B | ||
| INCY | INCYTE CORP | 16.23 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.34 | 14.24B |
Related stock screener links
About MYNZ
Company Profile
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 19 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Company Info
MAINZ BIOMED NV
Sirius Gutenberg Park, Robert-Koch-Strasse 50
MAINZ HESSEN DE
Employees: 19
Phone: 4961315542860
MAINZ BIOMED NV / MYNZ FAQ
What does MYNZ do?
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 19 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Can you provide the latest stock price for MAINZ BIOMED NV?
The current stock price of MYNZ is 1.26 USD. The price decreased by -11.89% in the last trading session.
What is the dividend status of MAINZ BIOMED NV?
MYNZ does not pay a dividend.
What is the ChartMill technical and fundamental rating of MYNZ stock?
MYNZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting MYNZ stock to perform?
7 analysts have analysed MYNZ and the average price target is 14.28 USD. This implies a price increase of 1033.33% is expected in the next year compared to the current price of 1.26.
What is the market capitalization of MYNZ stock?
MAINZ BIOMED NV (MYNZ) has a market capitalization of 6.82M USD. This makes MYNZ a Nano Cap stock.
Can you provide the ownership details for MYNZ stock?
You can find the ownership structure of MAINZ BIOMED NV (MYNZ) on the Ownership tab.
MYNZ Technical Analysis
MYNZ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MYNZ. Both the profitability and financial health of MYNZ have multiple concerns.
MYNZ Financial Highlights
Over the last trailing twelve months MYNZ reported a non-GAAP Earnings per Share(EPS) of -22.36. The EPS increased by 65.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -220.85% | ||
| ROE | -858.34% | ||
| Debt/Equity | 0.44 |
MYNZ Forecast & Estimates
7 analysts have analysed MYNZ and the average price target is 14.28 USD. This implies a price increase of 1033.33% is expected in the next year compared to the current price of 1.26.
For the next year, analysts expect an EPS growth of 83.39% and a revenue growth -17.68% for MYNZ